Literature DB >> 11719412

Differences between perspectives of physicians and patients on anticoagulation in patients with atrial fibrillation: observational study.

P J Devereaux1, D R Anderson, M J Gardner, W Putnam, G J Flowerdew, B F Brownell, S Nagpal, J L Cox.   

Abstract

OBJECTIVE: To determine and compare physicians' and patients' thresholds for how much reduction in risk of stroke is necessary and how much risk of excess bleeding is acceptable with antithrombotic treatment in people with atrial fibrillation.
DESIGN: Prospective observational study.
SETTING: Tertiary and peripheral referral centres in Nova Scotia, Canada. PARTICIPANTS: 63 physicians who were treating patients with atrial fibrillation and 61 patients at high risk for atrial fibrillation. MAIN OUTCOME MEASURES: Participants underwent a face to face interview with a probability trade-off tool. Thresholds were determined for the minimum reduction in risk of stroke necessary and the maximum increase in risk of excess bleeding acceptable for treatment with aspirin and warfarin in people with atrial fibrillation.
RESULTS: The minimum number of strokes that needed to be prevented in 100 patients over two years for warfarin to be justified was significantly lower for patients than for physicians (1.8 (SD 1.9) v 2.5 (1.6), P=0.009), whereas for aspirin there was no difference between patients and physicians (1.3 (1.3) v 1.6 (1.5), P=0.29). The maximum number of excess bleeds acceptable in 100 patients over two years for use of warfarin and aspirin was significantly higher for patients than for physicians (warfarin 17.4 (7.1) v 10.3 (6.1); aspirin 14.7 (8.5) v 6.7 (6.2); P<0.001 for both comparisons).
CONCLUSIONS: Patients at high risk for atrial fibrillation placed more value on the avoidance of stroke and less value on the avoidance of bleeding than did physicians who treat patients with atrial fibrillation. The views of the individual patient should be considered when decisions are being made about antithrombotic treatment for people with atrial fibrillation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11719412      PMCID: PMC59994          DOI: 10.1136/bmj.323.7323.1218

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  29 in total

1.  Preventing stroke in atrial fibrillation: why are so many eligible patients not receiving anticoagulant therapy?

Authors:  S J Connolly
Journal:  CMAJ       Date:  1999-09-07       Impact factor: 8.262

Review 2.  Patient choice modules for summaries of clinical effectiveness: a proposal.

Authors:  M Holmes-Rovner; H Llewellyn-Thomas; V Entwistle; A Coulter; A O'Connor; D R Rovner
Journal:  BMJ       Date:  2001-03-17

Review 3.  How do patients' treatment preferences compare with those of clinicians?

Authors:  A A Montgomery; T Fahey
Journal:  Qual Health Care       Date:  2001-09

4.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

5.  Patient preference-based treatment thresholds and recommendations: a comparison of decision-analytic modeling with the probability-tradeoff technique.

Authors:  M Man-Son-Hing; A Laupacis; A M O'Connor; D Coyle; R Berquist; F McAlister
Journal:  Med Decis Making       Date:  2000 Oct-Dec       Impact factor: 2.583

6.  Shared decision-making in primary care: the neglected second half of the consultation.

Authors:  G Elwyn; A Edwards; P Kinnersley
Journal:  Br J Gen Pract       Date:  1999-06       Impact factor: 5.386

7.  The impact of patients' preferences on the treatment of atrial fibrillation: observational study of patient based decision analysis.

Authors:  J Protheroe; T Fahey; A A Montgomery; T J Peters
Journal:  BMJ       Date:  2000-05-20

8.  The impact of long-term warfarin therapy on quality of life. Evidence from a randomized trial. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators.

Authors:  T R Lancaster; D E Singer; M A Sheehan; L B Oertel; S W Maraventano; R A Hughes; J P Kistler
Journal:  Arch Intern Med       Date:  1991-10

9.  Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.

Authors:  P A Wolf; R D Abbott; W B Kannel
Journal:  Stroke       Date:  1991-08       Impact factor: 7.914

10.  Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group.

Authors: 
Journal:  Lancet       Date:  1993-11-20       Impact factor: 79.321

View more
  101 in total

Review 1.  Balancing ischaemia and bleeding risks with novel oral anticoagulants.

Authors:  Usman Baber; Ioannis Mastoris; Roxana Mehran
Journal:  Nat Rev Cardiol       Date:  2014-11-04       Impact factor: 32.419

2.  Physicians' and patients' choices in evidence based practice.

Authors:  R Brian Haynes; P J Devereaux; Gordon H Guyatt
Journal:  BMJ       Date:  2002-06-08

Review 3.  Cardiology.

Authors:  Tom Fahey; Knut Schroeder
Journal:  Br J Gen Pract       Date:  2004-09       Impact factor: 5.386

4.  Death and disability from warfarin-associated intracranial and extracranial hemorrhages.

Authors:  Margaret C Fang; Alan S Go; Yuchiao Chang; Elaine M Hylek; Lori E Henault; Nancy G Jensvold; Daniel E Singer
Journal:  Am J Med       Date:  2007-05-24       Impact factor: 4.965

5.  Evidence based medicine has come a long way.

Authors:  Gordon Guyatt; Deborah Cook; Brian Haynes
Journal:  BMJ       Date:  2004-10-30

6.  Descriptive analysis of the process and quality of oral anticoagulation management in real-life practice in patients with chronic non-valvular atrial fibrillation: the international study of anticoagulation management (ISAM).

Authors:  Jack Ansell; Jennifer Hollowell; Vittorio Pengo; Fernando Martinez-Brotons; Jaime Caro; Ludovic Drouet
Journal:  J Thromb Thrombolysis       Date:  2007-04       Impact factor: 2.300

Review 7.  Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Samantha MacLean; Sohail Mulla; Elie A Akl; Milosz Jankowski; Per Olav Vandvik; Shanil Ebrahim; Shelley McLeod; Neera Bhatnagar; Gordon H Guyatt
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 8.  Developing a Conversation Aid to Support Shared Decision Making: Reflections on Designing Anticoagulation Choice.

Authors:  Claudia L Zeballos-Palacios; Ian G Hargraves; Peter A Noseworthy; Megan E Branda; Marleen Kunneman; Bruce Burnett; Michael R Gionfriddo; Christopher J McLeod; Haeshik Gorr; Juan Pablo Brito; Victor M Montori
Journal:  Mayo Clin Proc       Date:  2019-01-11       Impact factor: 7.616

9.  Values and preferences for oral antithrombotic therapy in patients with atrial fibrillation: physician and patient perspectives.

Authors:  Pablo Alonso-Coello; Victor M Montori; M Gloria Díaz; Philip J Devereaux; Gemma Mas; Ana I Diez; Ivan Solà; Mercè Roura; Juan C Souto; Sven Oliver; Rafael Ruiz; Blanca Coll-Vinent; Ignasi Gich; Holger J Schünemann; Gordon Guyatt
Journal:  Health Expect       Date:  2014-05-12       Impact factor: 3.377

10.  Health outcome priorities among competing cardiovascular, fall injury, and medication-related symptom outcomes.

Authors:  Mary E Tinetti; Gail J McAvay; Terri R Fried; Heather G Allore; Joanna C Salmon; Joanne M Foody; Luann Bianco; Sandra Ginter; Liana Fraenkel
Journal:  J Am Geriatr Soc       Date:  2008-07-24       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.